Long-lasting responses under treatment with ipilimumab: An argument against maintenance therapy?

Dermatology

Volumn 230, Issue 1, 2015, Pages 8-10

  Dick, Julika ^a   Enk, Alexander ^a   Hassel, Jessica Cecile ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Ipilimumab; Long term response; Maintenance therapy

Indexed keywords

BUDESONIDE; CARBOPLATIN; DACARBAZINE; GEMCITABINE; HYDROCORTISONE; IPILIMUMAB; MESALAZINE; PACLITAXEL; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SIZE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLITIS; COLON METASTASIS; COMPASSIONATE USE; CORTICOSTEROID THERAPY; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HUMAN; HUMAN CELL; HYPOPHYSITIS; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; DISEASE COURSE; MELANOMA; SECONDARY; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; DISEASE PROGRESSION; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84922874882     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000365078     Document Type: Article

References (12)

1. Little EG, Eide MJ: Update on the current state of melanoma incidence. Dermatol Clin 2012; 30:355-361.
2. Agarwala SS: Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9:587-595.
3. Hodi FS, et al: Improved survival with ipili-mumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
4. Robert C, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
5. Schadendorf D, Hauschild A: Melanoma in 2013: melanoma-the run of success continues. Nat Rev Clin Oncol 2014; 11:75-76.
6. Finn OJ: Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23(suppl 8):viii6-viii9.
7. Berinstein NL: Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Ann NY Acad Sci 2009; 1174:107-117.
8. Holmes JP, et al: Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008; 113: 1666-1675.
9. Tsaknakis B, et al: Long-lasting complete response of metastatic melanoma to ipilimu-mab with analysis of the resident immune cells. Med Oncol 2014; 31:813.
10. Attia P, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lym-phocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
11. Sanderson K, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lym-phocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741-750.
12. Downey SG, et al: Prognostic factors related to clinical response in patients with metastat-ic melanoma treated by CTL-associated anti-gen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.